Nir Eyal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7687025/publications.pdf

Version: 2024-02-01

97	1,634	430874	345221
papers	citations	18 h-index	36 g-index

100	100	100	2527
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
2	Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. Journal of Infectious Diseases, 2020, 221, 1752-1756.	4.0	186
3	Contact tracing performance during the Ebola epidemic in Liberia, 2014-2015. PLoS Neglected Tropical Diseases, 2018, 12, e0006762.	3.0	90
4	Non-physician Clinicians in Sub-Saharan Africa and the Evolving Role of Physicians. International Journal of Health Policy and Management, 2016, 5, 149-153.	0.9	52
5	Using informed consent to save trust. Journal of Medical Ethics, 2014, 40, 437-444.	1.8	49
6	Ethical Questions in Medical Electronic Adherence Monitoring. Journal of General Internal Medicine, 2016, 31, 338-342.	2.6	45
7	Challenges in clinical trial design for HIV-1 cure research. Lancet, The, 2013, 382, 1464-1465.	13.7	37
8	From Doxastic to Epistemic: A Typology and Critique of Qualitative Interview Styles. Qualitative Inquiry, 2020, 26, 291-305.	1.4	32
9	â€˜Perhaps the most important primary goodâ€™: self-respect and Rawlsâ€™s principles of justice. Politics, Philosophy & Economics, 2005, 4, 195-219.	1.0	31
10	Choices in vaccine trial design in epidemics of emerging infections. PLoS Medicine, 2018, 15, e1002632.	8.4	29
11	Scaling up changes in doctorsâ€™ education for rural retention: a comment on World Health Organization recommendations. Bulletin of the World Health Organization, 2011, 89, 83-83.	3.3	29
12	Improving vaccine trials in infectious disease emergencies. Science, 2017, 357, 153-156.	12.6	28
13	The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction. Journal of Medical Ethics, 2017, 43, 65-66.	1.8	28
14	Opinion: Risk to study nonparticipants: A procedural approach. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8051-8053.	7.1	26
15	Denial of Treatment to Obese Patientsâ€”the Wrong Policy on Personal Responsibility for Health. International Journal of Health Policy and Management, 2013, 1, 107-110.	0.9	24
16	Nudging by Shaming, Shaming by Nudging. International Journal of Health Policy and Management, 2014, 3, 53-56.	0.9	23
17	Why Challenge Trials of SARSâ€CoVâ€2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events. Ethics & Human Research, 2020, 42, 24-34.	0.9	23
18	Ethical issues in HIV remission trials. Current Opinion in HIV and AIDS, 2018, 13, 422-427.	3.8	22

#	Article	IF	Citations
19	Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. Journal of Infectious Diseases, 2019, 220, S1-S4.	4.0	21
20	HIV Treatment-as-Prevention Research at a Crossroads. PLoS Medicine, 2014, 11, e1001654.	8.4	18
21	Ebola and beyond. Science, 2015, 348, 46-48.	12.6	18
22	How to keep high-risk studies ethical: classifying candidate solutions. Journal of Medical Ethics, 2017, 43, 74-77.	1.8	17
23	Overcoming HIV Stigma? A Qualitative Analysis of HIV Cure Research and Stigma Among Men Who Have Sex with Men Living with HIV. Archives of Sexual Behavior, 2018, 47, 2061-2069.	1.9	16
24	Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines. Journal of Medical Ethics, 2020, 46, 808-812.	1.8	15
25	Adding Lithium to Drinking Water for Suicide Preventionâ€"The Ethics. Public Health Ethics, 2019, 12, 274-286.	1.0	14
26	How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach. Journal of Infectious Diseases, 2019, 220, S7-S11.	4.0	13
27	Repeat Triage in Disaster Relief: Questions from Haiti. PLOS Currents, 2012, 4, e4fbbdec6279ec.	1.4	13
28	Is the Body Special? Review of CÃ©cile Fabre, Whose Body is it Anyway? Justice and the Integrity of the Person. Utilitas, 2009, 21, 233-245.	0.5	12
29	Vaccine testing for emerging infections: the case for individual randomisation. Journal of Medical Ethics, 2017, 43, 625-631.	1.8	12
30	Ugandan Study Participants Experience Electronic Monitoring of Antiretroviral Therapy Adherence as Welcomed Pressure to Adhere. AIDS and Behavior, 2018, 22, 3363-3372.	2.7	12
31	HIV Cure Research: Risks Patients Expressed Willingness to Accept. Ethics & Human Research, 2019, 41, 23-34.	0.9	12
32	A staff support programme for rural hospitals in Nepal. Bulletin of the World Health Organization, 2016, 94, 65-70.	3.3	12
33	Broad cross-national public support for accelerated COVID-19 vaccine trial designs. Vaccine, 2021, 39, 309-316.	3.8	11
34	What can the lived experience of participating in risky HIV cure-related studies establish?. Journal of Medical Ethics, 2018, 44, medethics-2017-104593.	1.8	10
35	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. Journal of Virus Eradication, 2019, 5, 109-115.	0.5	10
36	Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure. Clinical Microbiology and Infection, 2021, 27, 372-377.	6.0	10

#	Article	IF	Citations
37	Making Fair Choices on the Path to Universal Health Coverage: Applying Principles to Difficult Cases. Health Systems and Reform, 2017, 3, 301-312.	1.2	10
38	The importance of how research participants think they are perceived: results from an electronic monitoring study of antiretroviral therapy in Uganda. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 761-766.	1.2	9
39	How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available. Clinical Infectious Diseases, 2021, 73, 2332-2334.	5.8	9
40	Regulating impact on bystanders in clinical trials: An unsettled frontier. Clinical Trials, 2019, 16, 450-454.	1.6	8
41	Rescuing Vapers Versus Rescuing Smokers: The Ethics. Nicotine and Tobacco Research, 2021, 23, 26-31.	2.6	8
42	Electronic Adherence Monitoring May Facilitate Intentional HIV Status Disclosure Among People Living with HIV in Rural Southwestern Uganda. AIDS and Behavior, 2021, 25, 2131-2138.	2.7	8
43	Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies. International Journal of Infectious Diseases, 2021, 105, 307-311.	3.3	8
44	Motivating Prevention: from Carrots and Sticks to â€œCarrotsâ€•and â€œSticksâ€• AMA Journal of Ethics, 2008, 10, 756-762.	0.7	7
45	Reconciling informed consent with prescription drug requirements. Journal of Medical Ethics, 2012, 38, 589-591.	1.8	7
46	Paying for antiretroviral adherence: is it unethical when the patient is an adolescent?. Journal of Medical Ethics, 2017, 43, 145-149.	1.8	7
47	When Ancillary Care Clashes with Study Aims. New England Journal of Medicine, 2017, 377, 1213-1215.	27.0	7
48	â€œCureâ€•Versus â€œClinical Remissionâ€• The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication. AIDS and Behavior, 2020, 24, 2054-2061.	2.7	7
49	AIDS Activism and Coronavirus Vaccine Challenge Trials. AIDS and Behavior, 2020, 24, 3302-3305.	2.7	7
50	Three Case Studies in Making Fair Choices on the Path to Universal Health Coverage. Health and Human Rights, 2016, 18, 11-22.	1.3	7
51	Is There a Moral Right to Nonmedical Vaccine Exemption?. American Journal of Law and Medicine, 2016, 42, 598-620.	0.2	6
52	Risk to bystanders in clinical trials: A symposium. Clinical Trials, 2019, 16, 447-449.	1.6	6
53	Response to Cioffi. Journal of Infectious Diseases, 2020, 222, 169-170.	4.0	6
54	On Knowingly Setting Unrealistic Goals in Public Health. American Journal of Public Health, 2020, 110, 480-484.	2.7	6

#	Article	IF	Citations
55	Do coronavirus vaccine challenge trials have a distinctive generalisability problem?. Journal of Medical Ethics, 2022, 48, 586-589.	1.8	6
56	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. Journal of Virus Eradication, 2019, 5, 109-115.	0.5	6
57	Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption?. Journal of Infectious Diseases, 2019, 220, S19-S21.	4.0	5
58	Removing One Barrier to Protecting Sex Partners in HIV Remission Studies With a Treatment Interruption. Journal of Infectious Diseases, 2019, 220, S22-S23.	4.0	5
59	COVID vaccine efficacy against the B.1.351 (â€œSouth Africanâ€) variantâ€”The urgent need to lay the groundwork for possible future challenge studies. Human Vaccines and Immunotherapeutics, 2021, , 1-2.	3.3	5
60	Informed consent, the value of trust, and hedons. Journal of Medical Ethics, 2014, 40, 447-447.	1.8	4
61	Unnecessary hesitancy on human vaccine tests. Science, 2020, 369, 150-151.	12.6	4
62	Symposium on risks to bystanders in clinical research: An introduction. Bioethics, 2020, 34, 879-882.	1.4	4
63	COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement. Journal of Medical Ethics, 2021, 47, 539-542.	1.8	4
64	Nudges and Noodges: The Ethics of Health Promotion--New York Style. Public Health Ethics, 2013, 6, 233-234.	1.0	3
65	Informed consent to participation in interventional studies: second-order in a different sense. Journal of Law and the Biosciences, 2015, 2, 123-128.	1.6	3
66	Ethical Issues in Disaster Medicine. , 2016, , 67-74.		3
67	Incommensurability and Trade. Monist, The, 2016, 99, 387-405.	0.5	3
68	Is There an Ethical Upper Limit on Risks to Study Participants?. Public Health Ethics, 2020, 13, 143-156.	1.0	3
69	The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants. Journal of Infectious Diseases, 2022, 225, 934-937.	4.0	3
70	Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests. Vaccine, 2021, 39, 3455-3458.	3.8	3
71	Pediatric heart surgery in Ghana: three ethical questions. Journal of Clinical Ethics, 2014, 25, 317-23.	0.3	3
72	One lesson of COVID-19: Conduct more health policy trials. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	3

#	Article	IF	Citations
73	Why Treat Noncompliant Patients? Beyond the Decent Minimum Account. Journal of Medicine and Philosophy, 2011, 36, 572-588.	0.8	2
74	Standard of care versus second-best: Ethical dilemmas in surgery for high risk papillary thyroid cancer in low and middle-income countries. Journal of Cancer Policy, 2015, 6, 8-10.	1.4	2
75	HIV Treatment-As-Prevention Research: Authorsâ€™ Reply. PLoS Medicine, 2015, 12, e1001799.	8.4	2
76	Invited Commentary on DubÃ© et al. (Perceptions of Equipoise, Risk/Benefit Ratios, and â€œOtherwise) Tj ETQq0 0 0 rgBT /Overlock 10 Otherwise Healthy?. Journal of Empirical Research on Human Research Ethics, 2018, 13, 18-22.	1.3	2
77	Inequality in Political Philosophy and in Epidemiology: A Remarriage. Journal of Applied Philosophy, 2018, 35, 149-167.	1.0	2
78	Ethical complexities of responding to bystander risk in HIV prevention trials. Clinical Trials, 2019, 16, 458-460.	1.6	2
79	Response to Dawson et al. Journal of Infectious Diseases, 2020, 222, 516-517.	4.0	2
80	â€œThought provokingâ€, â€œinteractiveâ€, and â€œmore like a peer talkâ€: Testing the deliberative interview style in Germany. SSM Qualitative Research in Health, 2021, 1, 100007.	1.5	2
81	Maximising the global health impact of future HIV cure-related interventions through advance planning. Journal of Virus Eradication, 2018, 4, 182-185.	0.5	2
82	â€œThe research assistants kept coming to follow me up; I counted myself as a lucky personâ€: Social support arising from a longitudinal HIV cohort study in Uganda. PLoS ONE, 2022, 17, e0262989.	2.5	2
83	Pandemic vaccine testing: Combining conventional and challenge studies. Pharmacoepidemiology and Drug Safety, 2022, , .	1.9	2
84	Coronavirus Disease 2019 (COVID-19) Vaccine Prioritization in Low- and Middle-Income Countries May Justifiably Depart From High-Income Countriesâ€™ Age Priorities. Clinical Infectious Diseases, 2022, 75, S93-S97.	5.8	2
85	Paternalism, French fries and the weak-willed Witness. Journal of Medical Ethics, 2014, 40, 353-354.	1.8	1
86	Opinion: Itâ€™s ethical to test promising coronavirus vaccines against less-promising ones. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18898-18901.	7.1	1
87	Study bystanders and ethical treatment of study participantsâ€”A proof of concept. Bioethics, 2020, 34, 941-947.	1.4	1
88	Input and output in distributive theory. Nous, 0, , .	2.2	1
89	Nudge, Embarrassment, and Restrictionâ€”Replies to Voigt, Tieffenbach, and Saghai. International Journal of Health Policy and Management, 2015, 4, 53-54.	0.9	1
90	Consent Requirements for Testing Health Policies: An Intercontinental Comparison of Expert Opinions. Journal of Empirical Research on Human Research Ethics, 0, , 155626462210767.	1.3	1

#	Article	IF	Citations
91	Afterword: returning to philosophical foundations in research ethics. Journal of Medical Ethics, 2017, 43, 132-133.	1.8	0
92	Support for UNRWA's survival. Lancet, The, 2018, 392, 1009-1010.	13.7	0
93	Reply to Hasford and to Spinola et al. Journal of Infectious Diseases, 2020, 222, 1574-1575.	4.0	0
94	Sticking with Carrots and Sticks (Sticking Points Aside): A Response to Ventakapuram, Goldberg, and Forrow. International Journal of Health Policy and Management, 2013, 1, 317-318.	0.9	0
95	Coordinating Between Medical Professionsâ€™ Tasks to Optimize Sub-Saharan Health Systems: A Response to Recent Commentaries. International Journal of Health Policy and Management, 2017, 6, 123-125.	0.9	0
96	Research ethics and public trust in vaccines: the case of COVID-19 challenge trials. Journal of Medical Ethics, 0, , medethics-2021-108086.	1.8	0
97	A new day for human challenge trials?. Trends in Molecular Medicine, 2022, , .	6.7	0